EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Transforming Pediatric Rare Disease Drug Development: Enhancing Clinical Trials and Regulatory Evidence With Virtual Patients

Fianne Sips, Marco Virgolin iD, Giuseppe Pasculli iD, Federico Reali iD, Alessio Paris iD, Annette Janus iD, Yann Godfrin, Daniel Röshammar iD, Luca Marchetti iD, Jane Knöchel iD

CPT: Pharmacometrics & Systems Pharmacology · 2025

DOI: 10.1002/psp4.70096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Fianne Sips und 9 weiteren Autor:innen. Beteiligte Einrichtung: InSilicoTrials Technologies BV, 's-Hertogenbosch, the Netherlands. Hauptthemen laut MEDLINE: Drug Development, Machine Learning, Rare Diseases, Computer Simulation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug development in pediatric rare diseases is complicated by practical and ethical constraints on clinical trial design, stemming from small, highly heterogeneous, and vulnerable patient populations. Virtual patients (VPs) created with machine‐learning (ML), mechanistically driven computational approaches, or hybrids thereof, have the potential to expedite and maximize the impact of trials. We discuss the potential of VPs to transform the efficiency and impact of clinical trials in pediatric rare diseases, based on adult and pediatric examples.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentMachine LearningRare DiseasesComputer SimulationDigital HealthHumansChildAdultClinical Trials as TopicNetwork Pharmacology

Autor:innen und Institutionen

  • InSilicoTrials Technologies BV, 's-Hertogenbosch, the Netherlands.
  • InSilicoTrials Technologies Spa, Trieste, Italy.
  • Fondazione the Microsoft Research - University of Trento Centre for Computational and Systems Biology (COSBI), Rovereto, Italy.
  • Axoltis Pharma, Bioparc Laennec, Lyon, France.
  • Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy.

ORCID-Profile: Marco Virgolin, Giuseppe Pasculli, Federico Reali, Alessio Paris, Annette Janus, Daniel Röshammar, Luca Marchetti, Jane Knöchel

Zitieren

APA

Sips, F., Virgolin, M., Pasculli, G., Reali, F., Paris, A., Janus, A., Godfrin, Y., Röshammar, D., Marchetti, L., & Knöchel, J. (2025). Transforming Pediatric Rare Disease Drug Development: Enhancing Clinical Trials and Regulatory Evidence With Virtual Patients. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70096

Vancouver

Sips F, Virgolin M, Pasculli G, Reali F, Paris A, Janus A, et al. Transforming Pediatric Rare Disease Drug Development: Enhancing Clinical Trials and Regulatory Evidence With Virtual Patients. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.70096

BibTeX
@article{Sips2025,
  author = {Sips, Fianne and Virgolin, Marco and Pasculli, Giuseppe and Reali, Federico and Paris, Alessio and Janus, Annette and Godfrin, Yann and Röshammar, Daniel and Marchetti, Luca and Knöchel, Jane},
  title = {Transforming Pediatric Rare Disease Drug Development: Enhancing Clinical Trials and Regulatory Evidence With Virtual Patients},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2025},
  doi = {10.1002/psp4.70096}
}
Kostenlos starten →